Motives and Side-Effects of Microdosing With Psychedelics Among Users
Open accessAbstract
Background: Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods: An online questionnaire was launched on several websites and fora between March and July 2018. Respondents who had consented, were 18 years of age or older, and had experience with microdosing were included in the analyses. Results: In total, 1116 of the respondents were either currently microdosing (79.5%) or microdosed in the past (20.5%). Lysergic acid diethylamide (10 mcg) and psilocybin (0.5 g) were the most commonly used psychedelics with a microdosing frequency between 2 and 4 times per week. The majority of users, however, were oblivious about the consumed dose. Performance enhancement was the main motive to microdose (37%). The most reported negative effects were of psychological nature and occurred acutely while under the influence. Conclusion: In line with media reports and anecdotes, the majority of our respondents microdosed to enhance performance. Negative effects occurred mostly acutely after substance consumption. However, the main reason to have stopped microdosing was that it was not effective. Future experimental placebo-controlled studies are needed to test whether performance enhancement can be quantified and to assess potential negative effects after longer term microdosing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cognitive Enhancement: Methods, Ethics, Regulatory Challenges
Bostrom, N., & Sandberg, A. (2009) · Science and Engineering Ethics · doi:10.1007/s11948-009-9142-5 · Cited by 757 · see citing works
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · see citing works
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · see citing works
Carbonaro, T. M., Bradstreet, M. P., Barrett, F., Maclean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662634 · Cited by 494 · see citing works
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236 · see citing works
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · cited 6× · see citing works
“A recent follow-up study found a mismatch between expected effects and the perceived psychological changes when microdosing for 6 weeks (Polito and Stevenson, 2019).”
BackgroundResultInfluentialExploring the effect of microdosing psychedelics on creativity in an open-label natural setting
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchar, M., Sjoerds, Z., & Hommel, B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5049-7 · Cited by 177 · see citing works
Yanakieva, S., Polychroni, N., Family, N., Williams, L. T. J., Luke, D. P., & Terhune, D. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5119-x · Cited by 167 · see citing works
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155 · cited 8× · see citing works
“The most reported microdoses of LSD (10 mcg) and psilocybin (0.5 g) are comparable with the doses reported in previous studies (Johnstad, 2018; Winstock et al., 2018; Polito and Stevenson, 2019) and in line with the reported one-tenth of a regular dose (Chandler, 2018; thethirdwave, 2018).”
BackgroundResultInfluentialThe Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys
Fadiman, J. (2011) · Cited by 141 · see citing works
Pharmacological cognitive enhancement—how neuroscientific research could advance ethical debate
Maslen, H., Faber, N. S., & Savulescu, J. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00107 · Cited by 98 · see citing works
Horsley, R. R., Páleníček, T., Kolin, J., & Valeš, K. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000394 · Cited by 52 · see citing works
Psychopathology and Psychophysiology of Minimal LSD-25 Dosage
GREINER, T. H. (1958) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1958.02340020088016 · Cited by 47 · see citing works
How cognitive enhancement can change our duties
de Sio, F. S., Faber, N. S., & Vincent, N. A. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00131 · Cited by 44 · see citing works
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
Andersson, C., Gry, J., & Kristinsson, J. (2009) · TemaNord · doi:10.6027/tn2008-606 · Cited by 41 · see citing works
Focusing the Neuroscience and Societal Implications of Cognitive Enhancers
Savulich, G., Piercy, T., Brühl, A. B., Fox, C., John Suckling, A., Rowe, J. B., O'Brien, J. T., & Sahakian, B. J. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.457 · Cited by 41 · see citing works
The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys
Rhead, J. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.948329 · Cited by 30 · see citing works
Garasic, M. D., & Lavazza, A. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00013 · Cited by 16 · see citing works
Responsible Cognitive Enhancement: Neuroethical Considerations
Colzato, L. S. (2018) · Journal of Cognitive Enhancement · doi:10.1007/s41465-018-0090-3 · Cited by 15 · see citing works
Use of LSD in the Haight-Ashbury. Observations at a neighborhood clinic.
Smith, D. E. (1969) · PubMed · Cited by 11 · see citing works
Wong, S. (2017) · The New Scientist · doi:10.1016/s0262-4079(17)31161-2 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Passie T (2019) The science of microdosing psychedelics. London: Psychedelic Press.
Cited by
Sorted by citations
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · see citing works
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
Kuypers, K., Ng, L., Erritzoe, D., Knudsen, G., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 188 · see citing works
Self-citationKettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221 · see citing works
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177 · see citing works
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · see citing works
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02039-0 · Cited by 148 · see citing works
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.002 · Cited by 123 · see citing works
Self-citationMicrodosing psychedelics: Motivations, subjective effects and harm reduction
Lea, T., Amada, N. M., Jungaberle, H., Schecke, H., & Klein, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.11.008 · Cited by 121 · see citing works
Polito, V., & Liknaitzky, P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104706 · Cited by 113 · see citing works
Psychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110 · see citing works
Investigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 104 · see citing works
The acute effects of classic psychedelics on memory in humans
Healy, C. J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05756-w · Cited by 95 · see citing works
Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 92 · see citing works
The therapeutic potential of microdosing psychedelics in depression
Kuypers, K. P. C. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320950567 · Cited by 85 · see citing works
Self-citationHutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00672 · Cited by 77 · see citing works
Rootman, J. M., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., Polito, V., Bourzat, F., & Walsh, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-01811-4 · Cited by 79 · see citing works
Self-citationLea, T., Amada, N. M., Jungaberle, H., Schecke, H., Scherbaum, N., & Klein, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05477-0 · Cited by 76 · see citing works
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities
Rosenbaum, D., Weissman, C., Anderson, T., Petranker, R., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908004 · Cited by 76 · see citing works
Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 70 · see citing works
Murphy, R. J., Sumner, R. L., Evans, W., Ponton, R., Ram, S., Godfrey, K., Forsyth, A., Cavadino, A., Naga, V. K., Smith, T., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.03.013 · Cited by 67 · see citing works
Holze, F., Liechti, M. E., Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Duthaler, U., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2057 · Cited by 65 · see citing works
Self-citationPsychedelics as a Treatment for Alzheimer’s Disease Dementia
Jones, S. V., & O’Kelly, A. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00034 · Cited by 62 · see citing works
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58 · see citing works
Oña, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58 · see citing works
Petranker, R., Anderson, T., Maier, L. J., Barratt, M. J., Ferris, J., & WINSTOCK, A. R. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120953994 · Cited by 57 · see citing works
Rootman, J. M., Kiraga, M. K., Kryskow, P., Harvey, K., Stamets, P. E., Santos-Brault, E., Kuypers, K. P. C., & Walsh, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-14512-3 · Cited by 57 · see citing works
Self-citationKloft, L., Monds, L. A., Blokland, A., Ramaekers, J. G., & Otgaar, H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.012 · Cited by 56 · see citing works
Trends in drug use among nightclub and festival attendees in New York City, 2017-2022
Palamar, J. J., Le, A., Cleland, C. M., & Keyes, K. M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104001 · Cited by 48 · see citing works
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Lazur, J., Hnatyk, K., Kała, K., Sułkowska‐Ziaja, K., & Muszyńska, B. (2023) · Antioxidants · doi:10.3390/antiox12030623 · Cited by 44 · see citing works
Rouaud, A., Calder, A. E., & Hasler, G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231225609 · Cited by 44 · see citing works
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 41 · see citing works
Psilocybin history, action and reaction: A narrative clinical review
Sharma, P., Nguyen, Q. A., Matthews, S. J., Carpenter, E., Matthews, D. B., Patten, C. A., & Hammond, C. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190858 · Cited by 38 · see citing works
Murray, C. H., Frohlich, J., Haggarty, C. J., Tare, I., Lee, R., & de Wit, H. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01809-2 · Cited by 36 · see citing works
Dose-response relationships of LSD-induced subjective experiences in humans
Hirschfeld, T., Prugger, J., Majić, T., & Schmidt, T. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01588-2 · Cited by 27 · see citing works
Bornemann, J. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1761573 · Cited by 24 · see citing works
Murphy, R. J., Sumner, R. L., Evans, W., Menkes, D. B., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Trials · doi:10.1186/s13063-021-05243-3 · Cited by 23 · see citing works
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 22 · see citing works
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 22 · see citing works
Psychedelics: Science sabotaged by Social Media
Sellers, E. M., & Romach, M. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109426 · Cited by 22 · see citing works
Donegan, C. J., Daldegan‐Bueno, D., Sumner, R. L., Menkes, D. B., Evans, W., Hoeh, N. R., Sundram, F., Reynolds, L., Ponton, R., Cavadino, A., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01399-8 · Cited by 21 · see citing works
Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.101012 · Cited by 20 · see citing works
Self-citationFrinculescu, A., Shine, T., Ramsey, J. M., Couchman, L., Frascione, N., & Abbate, V. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3629 · Cited by 20 · see citing works
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Yang, K. H., Satybaldiyeva, N., Allen, M. R., Ayers, J. W., & Leas, E. C. (2024) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.1653 · Cited by 19 · see citing works
Natural language signatures of psilocybin microdosing
Sanz, C., Cavanna, F., Muller, S. L., de la Fuente, L., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Carrillo, F., García, A. M., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06170-0 · Cited by 19 · see citing works
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 19 · see citing works
LSD increases sleep duration the night after microdosing
Allen, N. T., Jeremiah, A., Murphy, R. J., Sumner, R. L., Forsyth, A., Hoeh, N. R., Menkes, D. B., Evans, W., Muthukumaraswamy, S. D., Sundram, F., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02900-4 · Cited by 19 · see citing works
Basedow, L. A., Majić, T., Hafiz, N. J., Algharably, E. A. E., Kreutz, R. H., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-65391-9 · Cited by 19 · see citing works
Inserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 17 · see citing works
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
Liokaftos, D. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.103099 · Cited by 17 · see citing works
Mallaroni, P., Mason, N. L., Vinckenbosch, F. R. J., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06142-4 · Cited by 16 · see citing works
Self-citationHardon, A. P. (2020) · Critical studies in risk and uncertainty · doi:10.1007/978-3-030-57081-1 · Cited by 21 · see citing works
Keeping the promise: a critique of the current state of microdosing research
Petranker, R., Anderson, T., Fewster, E. C., Aberman, Y., Hazan, M., Gaffrey, M. S., & Seli, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1217102 · Cited by 15 · see citing works
Kinderlehrer, D. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s500337 · Cited by 15 · see citing works
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 14 · see citing works
Global Drug SurveyPreprint
Petranker, R., Anderson, T., Maier, L. J., Barratt, M. J., Ferris, J., & WINSTOCK, A. R. (2020) · doi:10.31234/osf.io/xb8ve · Cited by 14 · see citing works
Accounting for Microdosing Classic Psychedelics
Beaton, B., Copes, H., Webb, M. E., Hochstetler, A., & Hendricks, P. S. (2019) · Journal of Drug Issues · doi:10.1177/0022042619871008 · Cited by 13 · see citing works
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
Hartong, V., & van Emmerik, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2080616 · Cited by 11 · see citing works
“Lysergic acid diethylamide (LSD) and psilocybin mushrooms are the most commonly microdosed psychedelics, at a frequency of two to four times per week (Hutten et al. 2019; Johnstad 2018; Rosenbaum et al. 2020).”
BackgroundResultInfluentialExperiences of microdosing psychedelics in an attempt to support wellbeing and mental health
Ryan, R. S., Copello, A. G., & Fox, A. P. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04628-9 · Cited by 12 · see citing works
Less is more? A review of psilocybin microdosing
Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 12 · see citing works
A landscape analysis of psychedelic retreat organizations advertising online
Neitzke‐Spruill, L., Beit, C. S., Robinson, J. O., Singh, N., Kambala, S., Ramesh, R., & McGuire, A. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321648 · Cited by 12 · see citing works
Microdosing with classical psychedelics: Research trajectories and practical considerations
Wong, A., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221129115 · Cited by 11 · see citing works
Syed, O. A., Petranker, R., Fewster, E. C., Sobolenko, V., Beidas, Z., Husain, M. I., Lake, S., & Lucas, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424284 · Cited by 11 · see citing works
Wells, A., Muthukumaraswamy, A. P. S., Morunga, E., Evans, W. J., Cavadino, A., Bansal, M., Lawrence, N. J., Ashley, A., Hoeh, N., Sundram, F., et al. (2024) · Pilot and Feasibility Studies · doi:10.1186/s40814-024-01449-9 · Cited by 10 · see citing works
Modzelewski, S., Stankiewicz, A., Waszkiewicz, N., & Łukasiewicz, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110402 · Cited by 9 · see citing works
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8 · see citing works
Psychedelic Microdosing among Young Adults from Southern California
Harlow, A. F., Hendricks, P. S., Leventhal, A. M., & Barrington‐Trimis, J. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2313684 · Cited by 7 · see citing works
Korman, B. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00240 · Cited by 7 · see citing works
Kinderlehrer, D. A. (2023) · International Medical Case Reports Journal · doi:10.2147/imcrj.s395342 · Cited by 7 · see citing works
Al-Imam, A., Motyka, M. A., Witulska, Z., Younus, M. M., & Michalak, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116619 · Cited by 7 · see citing works
Cavanna, F., Muller, S. L., de la Fuente, L. A., Zamberlán, F., Palmucci, M., Janeckova, L., Kuchař, M., Pallavicini, C., & Tagliazucchi, E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470657 · Cited by 7 · see citing works
Between enhancement and risk: A critical review of psychedelic microdosing
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2025.102129 · Cited by 6 · see citing works
Self-citationJasemi, E., Razmi, A., Vaseghi, S., Amiri, S., & Najafi, S. M. A. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000813 · Cited by 6 · see citing works
Syed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 6 · see citing works
Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development
Simonsson, O., Stenfors, C. U. D., Goldberg, S. B., Hendricks, P. S., & Osika, W. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1151626 · Cited by 5 · see citing works
Psychedelic Drug Microdosing Practices: A Qualitative Online Exploration
Miller, E., Bojovic, V., Maddren, O., Rao, P., Adesina, D., Petrenko, A., & Ponton, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2304554 · Cited by 5 · see citing works
Neuroenhancement: State of the Art and Future Perspectives.
Marazziti, D., Avella, M. T., Ivaldi, T., Palermo, S., Massa, L., Vecchia, A. D., Basile, L., & Mucci, F. (2021) · PubMed Central · doi:10.36131/cnfioritieditore20210303 · Cited by 6 · see citing works
Jacobs, L., Banbury, S. A., & Lusher, J. M. (2022) · Sexual & Relationship Therapy · doi:10.1080/14681994.2022.2044466 · Cited by 5 · see citing works
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5 · see citing works
Korman, B. A. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231191400 · Cited by 5 · see citing works
Rominger, C., & Subow, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320755 · Cited by 4 · see citing works
Salvinorin A and Salvia divinorum: Toxicology, Pharmacological Profile, and Therapeutic Potential
Calado, S., Pires, B., Rosendo, L. M., Rosado, T., Gallardo, E., & Duarte, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125588 · Cited by 4 · see citing works
Donegan, C. J., Daldegan‐Bueno, D., Noorani, T. N., Sumner, R. L., Forsyth, A., Evans, W., Smith, T., Hoeh, N. R., Sundram, F., Menkes, D. B., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110670 · Cited by 4 · see citing works
Exploring the discourses around microdosing psychedelics within the r/microdosing online community
Pop, I. A., Gielens, E., Kottmann, H., & Achterberg, P. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.116702 · Cited by 4 · see citing works
Oblak, A., Hudnik, L. K., Levačić, A., Elersič, K., Pregelj, P., & Bon, J. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2393690 · Cited by 4 · see citing works
Barker, S. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111259 · Cited by 4 · see citing works
Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse
Brito-da-Costa, A. M., da Silva, D. D., Madureira-Carvalho, Á., & Dinis‐Oliveira, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_130-1 · Cited by 4 · see citing works
Microdosing Psychedelics as a Promising New Pharmacotherapeutic
Kuypers, K. P. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_18 · Cited by 4 · see citing works
Self-citationMicrodosing psychedelics – Does it have an impact on emodiversity?
Pop, I. A., & Dinkelacker, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00208 · Cited by 4 · see citing works
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4 · see citing works
Stanger, M., Soffer, H. O., Bryan, A. D., & Skrzynski, C. J. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2024.0059 · Cited by 2 · see citing works
Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature
Beaton, B. (2026) · Deviant Behavior · doi:10.1080/01639625.2026.2624690 · Cited by 2 · see citing works
Drange, S., Cohen, J., Johansen, S., Dunkley, B., & Palner, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1819962 · Cited by 2 · see citing works
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Diab, H., & Malcolm, B. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1847366 · Cited by 2 · see citing works
O'Connor, S., Godfrey, K., Reed, S., Peill, J. M., Rohani-Shukla, C., Healy, M., Robbins, T. W., de Souza, A. M. F. L. P., Tyacke, R. J., Papasyrou, M., et al. (2025) · Cureus · doi:10.7759/cureus.78171 · Cited by 2 · see citing works
Psychedelic Microdosing: What Is It Good For?
Bershad, A. K. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.06.021 · Cited by 2 · see citing works
Polito, V., & Liknaitzky, P. (2021) · doi:10.31234/osf.io/edhqz · Cited by 2 · see citing works
University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis
Frinton, S., & Robinson, J. O. (2025) · Journal of Drug Issues · doi:10.1177/00220426251338187 · Cited by 1 · see citing works
Cavarra, M., Hutten, N. R. P. W., Schepers, J., Mason, N. L., Theunissen, E. L., Liechti, M. E., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2025) · British Journal of Pain · doi:10.1177/20494637251371626 · Cited by 1 · see citing works
Self-citationBeidas, Z., Ragnhildstveit, A., Blackman, A., Anderson, T., Fewster, E. C., Syed, O. A., Sobolenko, V., Kanca, I. K., Jaglinska, M., Son, T., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2025.10968 · Cited by 1 · see citing works
- Authors
- Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C.
- Affiliations
- Maastricht University (NL)
- Corresponding author
- Hutten, Nadia R P W
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-31
- Volume
- 22
- Issue
- 7
- Pages
- 426-434
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6600464
- OpenAlex
- W2946918750
- Cited by
- 126
- References
- 21
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 19 · 2023: 19 · 2022: 18 · 2021: 16 · 2020: 19 · 2019: 4
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by-nc)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- microdosing, psychedelics, lysergic acid diethylamide, psilocybin, performance improvement, adverse outcomes, dosing frequency, user experience
- MeSH terms
- Adult, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Motivation, Psilocybin, Surveys and Questionnaires, Substance-Related Disorders, Performance-Enhancing Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
